Drugs.com - Clinical Trials

Nitric Oxide Can Alter Brain Function

Wed, 26 Nov 2008 19:55:59 GMT

Finding has implications for the treatment of neurodegenerative disease and dementia LEICESTER, England, Nov. 26,2008--Research from the Medical Research Council (MRC) Toxicology Unit at the University of Leicester shows that nitric oxide (NO) can...

Study Compares Strategies for BK Virus Nephropathy

Wed, 26 Nov 2008 19:50:44 GMT

Aggressive Reduction of Immunosuppression Lowers Risk of Kidney Loss in Transplant Recipients WASHINGTON, Nov. 26, 2008 — For kidney transplant recipients with a serious complication called BK virus-associated nephropathy (BKVAN),...

Flamel Technologies Update

Wed, 26 Nov 2008 17:00:38 GMT

CEDEX, France, Nov. 26, 2008-Flamel Technologies has posted an updated presentation on its website. The new presentation accounts for the initiation of an additional feasibility study to evaluate Medusa in conjunction with therapeutic...

Growth hormone not beneficial for ALS

Wed, 26 Nov 2008 15:50:31 GMT

ST. PAUL, Minn., Nov. 24, 2008 – A growth hormone that had shown some promise for treating people with amyotrophic lateral sclerosis (ALS) showed no benefit in a new study published in the November 25, 2008, issue of Neurology, the medical...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

Wed, 26 Nov 2008 15:10:41 GMT

SAN DIEGO, November 26, 2008 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, today reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not...

Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous Relistor for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain

Wed, 26 Nov 2008 13:45:08 GMT

-- Primary and key secondary efficacy endpoints achieved -- COLLEGEVILLE, Pa. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Nov 26, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced...

Stanford/Packard Study Shows No Benefit From Drug Widely Used to Prevent Premature Births

Wed, 26 Nov 2008 13:30:16 GMT

STANFORD, Calif.--(BUSINESS WIRE)--Nov 26, 2008 - When a pregnant woman goes into early labor, her obstetrician may give her drugs to quiet the woman's uterus and prevent premature birth. New research shows, however, that one popular drug works no...

Press Release: Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue

Tue, 25 Nov 2008 21:15:54 GMT

SAN MARINO, Calif., Nov. 25, 2008 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant...

Telcagepant Proven as a Safe and Effective Migraine Treatment in Phase III Trial

Tue, 25 Nov 2008 17:00:18 GMT

NEW YORK, Nov. 25, 2008-Telcagepant 300 mg is effective as an acute treatment for migraine with efficacy comparable to that of zolmitriptan 5 mg, a widely-used migraine treatment, but with fewer associated adverse effects. These are the conclusions...

Aegera Therapeutics' Phase 1/2 Clinical Trial Results Selected for Oral Presentation at 2008 ASH Annual Meeting

Tue, 25 Nov 2008 15:05:16 GMT

MONTREAL, November 25, 2008 /PRNewswire/ - Aegera Therapeutics Inc. today announced that data from its phase 1/2 clinical trial of the XIAP antisense oligonucleotide, AEG35156, will be highlighted in an oral presentation at the 50th Annual Meeting...

ERYtech Pharma Presents a New Advance in the Treatment of Sickle Cell Anaemia

Tue, 25 Nov 2008 14:55:01 GMT

LYON, France & PHILADELPHIA--(BUSINESS WIRE)--Nov 25, 2008 - ERYtech Pharma has been chosen to present the first pre-clinical results obtained with its product GR-ARA1 on sickle cell anaemia during the 50th annual congress of the American Society of...

Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology

Tue, 25 Nov 2008 14:25:30 GMT

Initial Results from Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Relapsed Multiple Myeloma Featured in Oral Presentations SOUTH SAN FRANCISCO, Calif., November 25, 2008 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and...

Protox announces positive Phase 2 BPH results

Mon, 24 Nov 2008 21:30:46 GMT

VANCOUVER, Nov. 24 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive data from its Phase 2 study of PRX302 in patients with benign prostatic hyperplasia (BPH), a...

Schering-Plough Unveils Top-Line Study Results for SAPHRIS (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention

Mon, 24 Nov 2008 20:20:31 GMT

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today revealed top-line results of a long-term Phase III clinical study of its psychopharmacologic agent SAPHRIS(TM) (asenapine) demonstrating efficacy...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

Mon, 24 Nov 2008 20:10:46 GMT

Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today provided a clinical update on boceprevir, its lead...

Labopharm to Host Webcast Presentation on Novel Trazodone Formulation for Treatment of Major Depressive Disorder

Mon, 24 Nov 2008 19:35:17 GMT

LAVAL, QC, November 24, 2008 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will host a webcast presentation on Tuesday, December 16, 2008 at 10:00 am (ET) during which the Company's senior management team will discuss the product...

Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease

Mon, 24 Nov 2008 16:25:39 GMT

KENILWORTH, N.J., November 24, 2008 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that preladenant, its novel and selective adenosine2a receptor antagonist, met the primary endpoint in a Phase II dose-finding trial in patients...

New Cancer Treatment Shrinks Pancreatic Tumor

Mon, 24 Nov 2008 15:55:58 GMT

NASHVILLE, Tenn., November 24, 2008 /PRNewswire/ -- A new cancer treatment is realizing outstanding results against pancreatic cancer. Following five weeks of treatment, a patient's large, stage 4 tumor was reduced in size by 70%. After seven more...

Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival in Advanced Breast Cancer

Mon, 24 Nov 2008 15:50:53 GMT

-- First Phase III Study (RIBBON 1) to Show Avastin's PFS Benefit with Capecitabine, as well as with Anthracycline-based Chemotherapies -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 24, 2008 - Genentech, Inc. (NYSE:DNA) today announced that...

Peregrine's Anti-Viral Bavituximab in Nature Medicine

Mon, 24 Nov 2008 14:30:57 GMT

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals’ Bavituximab to Cure Lethal Virus Infections —PS-Targeting Antibodies May Represent a Completely New Class of Drugs with Broad Potential to Treat...

Testosterone Effective in Female Sexual Dysfunction; BioSante Conducting Long-Term Safety Study of LibiGel in FSD

Mon, 24 Nov 2008 14:25:21 GMT

Company Comments on Paper in the New England Journal of Medicine LINCOLNSHIRE, Ill.--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception,...

Largest-ever studies on most common form of adult leukemia, show patients treated with MabThera live longer without disease progressing

Mon, 24 Nov 2008 14:21:00 GMT

Two Phase III studies to be presented at world’s major hematology meeting prove MabThera’s benefits in treating chronic lymphocytic leukemia (CLL) Basel, Switzerland – 24 November 2008. Roche announced today that full results of the pivotal...

ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action

Mon, 24 Nov 2008 14:16:00 GMT

VANCOUVER, British Columbia, Nov. 10 /CNW/ -- ProtoKinetix Inc. (OTC Bulletin Board: PKTX), a biotech company focused on the research, development and commercialization of patented anti-aging glycopeptides (AAGPs(TM)) announced today that its...

Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase IIb Study

Mon, 24 Nov 2008 13:51:01 GMT

-- Continues to Demonstrate Similar Efficacy to Ribavirin with Lower Anemia -- ALISO VIEJO, Calif.--(BUSINESS WIRE)--Nov 24, 2008 - Valeant Pharmaceuticals (NYSE:VRX) today reported results at end of treatment, week 48 analysis point in the Phase...

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections

Mon, 24 Nov 2008 13:20:48 GMT

TUSTIN, Calif., November 24, 2008 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. today reported publication of data in that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody...

Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results

Mon, 24 Nov 2008 13:15:35 GMT

First CINOD Meets all Three Co-primary Endpoints (p<0.001) in the 303 Hip Osteoarthritis (OA) Study and Shows no Detrimental Effect on Blood Pressure SOPHIA ANTIPOLIS, France, November 24, 2008 /PRNewswire-FirstCall/ -- NicOx S.A. today announced...

ARIAD to Present Preclinical Data on Multi-Targeted Kinase Inhibitor at 50th Ash Annual Meeting

Mon, 24 Nov 2008 13:10:16 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 24, 2008 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the company and collaborating investigators from the Howard Hughes Medical Institute and Oregon Health & Science University Cancer...

Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented

Mon, 24 Nov 2008 12:55:56 GMT

Overall Median Survival Extends to 10.5 months in Patients after Surgery with Multiple Recurrent Brain Cancer LAS VEGAS & NEW YORK & MOSCOW--(BUSINESS WIRE)--Nov 24, 2008 - Antigenics Inc. (NASDAQ: AGEN) today announced an oral presentation of...

Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile

Mon, 24 Nov 2008 12:45:43 GMT

-Phase I/II studies summarized- BELLEVILLE, ON, November 24, 2008 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, presented data about its proprietary...

Transgene’s TG1042 meets primary end point in step one of cutaneous B-cell lymphoma Phase II trial

Fri, 21 Nov 2008 21:10:06 GMT

Strasbourg, France, November 21, 2008 – Transgene (Euronext Paris: FR0005175080) today announced that the primary end point has been met in the first step of the ongoing Phase II trial with its immunotherapy product TG1042 (Ad-IFN•) in...

Study shows GE Healthcare's Visipaque Associated with Lower Incidence of Contrast-Induced Nephropathy and Cardiovascular Events in Patients with Chronic Kidney Disease Compared to Iopromide

Fri, 21 Nov 2008 17:40:15 GMT

PRINCETON, N.J.--(BUSINESS WIRE)--Nov 21, 2008 - A first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of GE Healthcare's isosmolar contrast media (CM) iodixanol...

Iressa Proves Just as Effective as Chemotherapy for Lung Cancer Findings Represent First Time Oral Therapy Tested Head-to-Head Against Standard Therapy; Surprising Biomarker Results

Fri, 21 Nov 2008 17:30:23 GMT

HOUSTON, Nov. 20, 2008--Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of non-small cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease with far fewer side...

Burzynski Research Institute, Inc. (BRI) Presents Promising Phase II Data on Malignant Glioma

Fri, 21 Nov 2008 15:20:40 GMT

HOUSTON & LAS VEGAS--(BUSINESS WIRE)--Nov 21, 2008 - Today at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology, BRI announced encouraging results from the ongoing Phase II clinical trials of two of its investigational drugs,...

New Study Data: Januvia (sitagliptin) Significantly Reduced Blood Sugar Levels and Was Not Associated with Hypoglycemia in Elderly Patients with Type 2 Diabetes

Fri, 21 Nov 2008 15:10:20 GMT

NATIONAL HARBOR, Md.--(BUSINESS WIRE)--Nov 21, 2008 - New data presented at the 61st Annual Scientific Meeting of the Gerontological Society of America showed JANUVIA™ (sitagliptin), a diabetes medicine from Merck & Co., Inc., significantly...

Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia

Fri, 21 Nov 2008 14:50:09 GMT

PRELIMINARY TOP LINE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNIFICANT DECREASES IN PAIN AND FATIGUE, AND IMPROVEMENT IN DAILY FUNCTION, IN FIBROMYALGIA PATIENTS PALO ALTO, Calif., and BRUSSELS,...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies

Fri, 21 Nov 2008 13:20:04 GMT

SAN MARINO, Calif., November 20, 2008 /PRNewswire/ -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P....

Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology

Thu, 20 Nov 2008 19:35:14 GMT

EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for...

Biovitrum and Symphogen Report Positive Clinical Results in Novel Rh-immunization Prevention Project

Thu, 20 Nov 2008 18:25:52 GMT

STOCKHOLM, Sweden and COPENHAGEN, Denmark - November 20, 2008. Biovitrum AB (publ) (STO:BVT) and Symphogen A/S have completed the first part of a clinical proof of mechanism study of the recombinant human polyclonal antibody product Sym001 for...

Thought Leaders from Burzynski Research Institute, Inc. Present Encouraging Data on Antineoplastons for Treatment of Malignant Gliomas

Thu, 20 Nov 2008 15:40:38 GMT

HOUSTON & LAS VEGAS--(BUSINESS WIRE)--Nov 20, 2008 - Several thought leaders from the Burzynski Research Institute, Inc. (BRI) and the Burzynski Clinic (BC) in Houston, Texas are presenting at the 13th Annual Scientific Meeting of the Society for...

Gloucester Pharmaceuticals to Present Positive Results from Multiple Romidepsin Clinical Trials at the ASH Annual Meeting

Thu, 20 Nov 2008 15:40:16 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2008 - Gloucester Pharmaceuticals today announced four presentations from clinical trials of romidepsin at the upcoming 50th American Society of Hematology (ASH) Annual Meeting being held in San Francisco,...